Analyst Ratings For Indivior PLC (LON:INDV)
Today, Citigroup Inc. raised its price target on Indivior PLC (LON:INDV) to GBX 340 per share.
There are 2 hold ratings, 5 buy ratings on the stock.
The current consensus rating on Indivior PLC (LON:INDV) is Buy (Score: 2.71) with a consensus target price of GBX 404.29 per share, a potential .
Some recent analyst ratings include
- 2/23/2017-Deutsche Bank AG Reiterated Rating of Buy.
- 2/22/2017-Numis Securities Ltd Reiterated Rating of Buy.
- 2/3/2017-Stifel Nicolaus Reiterated Rating of Buy.
About Indivior PLC (LON:INDV)
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of prescription drugs that are based on buprenorphine for treatment of opioid dependence segment. The Company’s treatment and pipeline focuses on opioid use disorder, alcohol use disorder, overdose rescue and co-morbidities of addiction/schizophrenia. Indivior’s products, which are sold in over 40 countries, consist of Suboxone film (buprenorphine and naloxone), Suboxone tablet (buprenorphine and naloxone) and Subutex tablet (buprenorphine sublingual tablet), all of which are used to treat opioid dependence. Its Buprenorphine lifecycle includes Suboxone Tablet, Suboxone Film, Buprenorphine Monthly Depot and Oral Swallowable Capsule. Its overdose rescue product category includes Cocaine Esterase. Its alcohol use disorders product category includes Arbaclofen Placarbil. Its adjacency-schizophrenia product category includes Risperidone Monthly Depot.
Recent Trading Activity for Indivior PLC (LON:INDV)
Shares of Indivior PLC closed the previous trading session at 351.00 down -5.00 -1.40% with 1,952,754 shares trading hands.